NCT06590974 A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency
| NCT ID | NCT06590974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Protein C Deficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 7 participants |
| Start Date | 2024-09-06 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7 participants in total. It began in 2024-09-06 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is conducted in Japan of Freeze-dried Human Protein C Concentrate (TAK-662) used to treat participants with congenital protein C deficiency. The main aim of the study is to evaluate for adverse events and effectiveness of congenital protein C deficiency (TAK-662). During the study, participants with congenital protein C deficiency will be administered with TAK-662 intravenous injection in under routine normal practice. The investigators will evaluate adverse events due to TAK-662 for 12 months. For participants who will be administered in long-term supplementation of TAK-662 after acute treatment or short-term supplementation, the investigator will evaluate for 24 months as a maximum. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.
Eligibility Criteria
Inclusion Criteria: \- All participants with congenital protein C deficiency who are administered with Freeze-dried Human Protein C Concentrate (TAK-662). Exclusion Criteria: \- None
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT06590974 clinical trial?
This trial is open to participants of all sexes, studying Protein C Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06590974 currently recruiting?
Yes, NCT06590974 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT06590974 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT06590974 clinical trial?
NCT06590974 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 7 participants.